Zydus follitropin alfa
Follitropin alfa biosimilar developed by Cadila Healthcare (Zydus Lifesciences). Reference product Gonal-f.
About Zydus follitropin alfa
Zydus, then Cadila Healthcare, received its follitropin alfa permission in India in January 2018, the third Indian maker.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Zydus follitropin alfa holds an approval, these are the other follitropin alfa biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 2 | Intas Pharmaceuticals (Intas follitropin alfa), Reliance Life Sciences (Reliance Life Sciences follitropin alfa) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Zydus Lifesciences: Exemptia / Cadalimab, Nufymco, Zydus aflibercept, Zydus bevacizumab, Zydus epoetin, Zydus peginterferon alfa-2b, Zydus pertuzumab, Zydus rituximab, Zydus teriparatide, Zydus trastuzumab.
Chronology
- CDSCOJan 2018CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning follitropin alfa biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant